ODAK is an FP7 funded project undertaking research and clinical development of PHMB for the treatment of Acanthamoeba keratitis.
The aim is to develop the first approved, safe and effective drug for this rare ocular disease.
A Phase III clinical study is ongoing in the UK, Poland and Italy.
The project is led by SIFI SpA, collaborating with Moorfields Eye Hospital, PSR Group BV, Ceratium Ltd, University of Rouen, and RTC SpA.
The ODAK project has received research funding from the European Union under the Framework Programme 7 Health 2012 call: Grant Agreement number 305661.